newsfilter
← Latest News
GlobeNewswire·

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies